Dr. Malik - Nuclear Care

Dr. Malik - Nuclear Care Discover the latest innovation happening in Nuclear medicine and how they can benefit patients.

Solving the Mysterical NETs.
22/07/2024

Solving the Mysterical NETs.

Solving the mysterical Neuro-endocrine tumors (NETs).  ,      -177prrt
08/07/2024

Solving the mysterical Neuro-endocrine tumors (NETs).

, -177prrt

VISION trial (shortcomings)
04/07/2024

VISION trial (shortcomings)

VISION trial: A landmark study, bringing Lu-177 PSMA therapy to mainstream.
01/07/2024

VISION trial: A landmark study, bringing Lu-177 PSMA therapy to mainstream.

ENZA-P trial : Suggests potential broader application of LuPSMA in mCRPC.
27/06/2024

ENZA-P trial : Suggests potential broader application of LuPSMA in mCRPC.

TARE: a game changing revolution  in hepatocellular carcinoma (HCC).
24/06/2024

TARE: a game changing revolution in hepatocellular carcinoma (HCC).

Pluvicto (LuPSMA) therapy: A gamechanger in metastatic prostate cancer.
20/06/2024

Pluvicto (LuPSMA) therapy: A gamechanger in metastatic prostate cancer.

Summary PSMAfore trial A great leap forward for Lu-177PSMA (Pluvicto) therapy.
17/06/2024

Summary PSMAfore trial

A great leap forward for Lu-177PSMA (Pluvicto) therapy.

The NETTER-2 trial aimed to investigate the efficacy and safety of first-line treatment with [Lu]Lu-DOTA-TATE (Lu-Dotata...
11/06/2024

The NETTER-2 trial aimed to investigate the efficacy and safety of first-line treatment with [Lu]Lu-DOTA-TATE (Lu-Dotatate).

Address

Dept. Of Nuclear Medicine, Fortis Memorial Research Institute (FMRI), Sector 44, Opposite HUDA City Center)
Gurugram
122001

Opening Hours

Monday 9am - 6pm
Tuesday 9am - 6pm
Wednesday 9am - 6pm
Thursday 9am - 6pm
Friday 9am - 6pm
Saturday 9am - 6pm

Telephone

+919625712300

Alerts

Be the first to know and let us send you an email when Dr. Malik - Nuclear Care posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Dr. Malik - Nuclear Care:

Share